The GLP-1 Class: An Overview
Over the past decade, GLP-1 receptor agonist peptides have become some of the most intensely studied compounds in metabolic research. Three peptides in particular — Semaglutide, Tirzepatide, and Retatrutide — have generated significant scientific interest due to their distinct mechanisms and research profiles.
Here is a breakdown of each for research context.
Semaglutide — The GLP-1 Pioneer
Semaglutide is a GLP-1 receptor agonist — it mimics the action of the naturally occurring glucagon-like peptide-1 hormone, which plays a key role in insulin secretion, gastric emptying, and appetite signaling.
- Mechanism: Single agonist (GLP-1 receptor only)
- Research focus: Metabolic regulation, weight-related outcomes, glycemic control
- Notable characteristic: Long half-life (~7 days), making it suitable for weekly administration protocols in research models
- Pharmaceutical analog: Ozempic, Wegovy (not our products — for reference only)
Tirzepatide — The Dual Agonist
Tirzepatide introduced a new class by targeting two receptors simultaneously — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone involved in energy homeostasis.
- Mechanism: Dual agonist (GLP-1 + GIP receptors)
- Research focus: Enhanced metabolic outcomes compared to single-agonist models, adipose tissue research, insulin sensitivity
- Notable characteristic: The addition of GIP agonism appears to produce additive or synergistic effects in research settings
- Pharmaceutical analog: Mounjaro, Zepbound (not our products — for reference only)
Retatrutide — The Triple Agonist
Retatrutide represents the next frontier — a triple receptor agonist targeting GLP-1, GIP, and the glucagon receptor simultaneously. Glucagon plays a critical role in energy expenditure and fat oxidation.
- Mechanism: Triple agonist (GLP-1 + GIP + Glucagon receptors)
- Research focus: Significant weight-related outcomes, energy expenditure, lipid metabolism
- Notable characteristic: Early-phase trials showed notably robust results; still under active clinical investigation
- Status: Not yet FDA-approved in any form — available strictly as a research peptide
Quick Comparison Table
| Peptide | Receptors Targeted | Research Stage |
|---|---|---|
| Semaglutide | GLP-1 | Extensive — Phase 3+ completed |
| Tirzepatide | GLP-1 + GIP | Extensive — FDA approved (pharma form) |
| Retatrutide | GLP-1 + GIP + Glucagon | Early-phase trials ongoing |
Which Should Researchers Choose?
The right choice depends entirely on your research objectives. Semaglutide offers the most extensive published literature. Tirzepatide provides a dual-mechanism model for comparative research. Retatrutide offers cutting-edge triple-agonist data for researchers looking at the leading edge of metabolic peptide science.
All three are available at My Freedom Peptides, third-party tested for 99%+ purity.
All products are for research use only. Not intended for human consumption or medical use.
The Freedom Files
Don’t Miss the Next Article
Join our email list for weekly research insights, new product drops, and exclusive deals.
Join the ListFor research use only. Not intended for human consumption. These statements have not been evaluated by the Food and Drug Administration.
Frequently Asked Questions
What is the main difference between Semaglutide, Tirzepatide, and Retatrutide?
Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide is a triple GLP-1/GIP/glucagon agonist. Each generation adds receptor targets, producing incrementally greater metabolic research outcomes.
Which has shown the most weight reduction in research?
Retatrutide has documented the largest reductions — over 24% in phase II trials. Tirzepatide follows at ~21% (SURMOUNT-1). Semaglutide documented ~15% (STEP-1). All figures are from research subjects under controlled conditions.
Which peptide has the longest half-life?
Semaglutide has the longest half-life at approximately 7 days. Tirzepatide is approximately 5 days. Retatrutide is approximately 6 days. All three support once-weekly dosing in research protocols.
Are all three available at My Freedom Peptides?
Yes. Semaglutide (1G-SGT), Tirzepatide (2G-TZ), and Retatrutide (3G-RT) are all available with batch-specific CoA documentation. All three have independent third-party purity and identity verification.
Which should a researcher choose?
The choice depends on the research question. Semaglutide offers the most published data. Tirzepatide offers dual-pathway mechanistic research. Retatrutide enables triple-receptor research with the broadest metabolic scope. All are for research use only.